Wallner LP, et al. - Researchers compared the risk of mortality among men treated for benign prostatic hyperplasia (BPH) with 5α-reductase inhibitors (5ARI) to those treated with alpha-blockers (AB) in community practice settings. When compared to alpha-blocker use, findings did not suggest an association of 5α-reductase inhibitor with an increased risk of mortality among men receiving medications for BPH in community practice settings. Reassurance regarding the safety of 5ARIs use in general practice to manage BPH/LUTS was provided in the findings.